ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced it intends to launch an initial public offering (IPO) on the Taipei Exchange in mid May and expects to start trading in early June 2017. ASLAN will be holding an auction for its proposed IPO in mid May.
An investor forum will be held on 27 April 2017 at Le Meridien Taipei.
The company has also received approval from the China Food and Drug Administration to initiate a phase 2 study of its lead asset, varlitinib, for the treatment of biliary tract cancer. The phase 2 study will investigate the efficacy of varlitinib as a second line therapy for patients with biliary tract cancer. ASLAN is also initiating a global pivotal study for varlitinib in biliary tract cancer following approval from US FDA. These two clinical studies are part of ASLAN’s strategy to secure global approvals for varlitinib in biliary tract cancer.